2000
Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging
Federle M, Chezmar J, Rubin D, Weinreb J, Freeny P, Schmiedl U, Brown J, Borrello J, Lee J, Semelka R, Mattrey R, Dachman A, Saini S, Harms S, Mitchell D, Anderson M, Halford H, Bennett W, Young S, Rifkin M, Gay S, Ballerini R, Sherwin P, Robison R. Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging. Journal Of Magnetic Resonance Imaging 2000, 12: 689-701. PMID: 11050638, DOI: 10.1002/1522-2586(200011)12:5<689::aid-jmri5>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsUnenhanced magnetic resonance imagingMagnetic resonance imagingMangafodipir trisodium injectionFinal diagnosisMulticenter phase III clinical trialContrast-enhanced computed tomography examinationPhase III clinical trialsContrast-enhanced magnetic resonance imagingInjection of MnDPDPPatient's final diagnosisHepatic magnetic resonance imagingComputed tomography examinationEnhanced magnetic resonance imagingFocal liver diseaseAdditional diagnostic informationFocal liver lesionsLiver diseaseEarly imagingMRI evaluationHepatic massClinical trialsTomography examinationIntravenous administrationPatient managementRadiologic diagnosisSafety and Efficacy of Mangafodipir Trisodium (MnDPDP) Injection for Hepatic MRI in Adults: Results of the U.S. Multicenter Phase III Clinical Trials (Safety)
Federle M, Chezmar J, Rubin D, Weinreb J, Freeny P, Semelka R, Brown J, Borrello J, Lee J, Mattrey R, Dachman A, Saini S, Harmon B, Fenstermacher M, Pelsang R, Harms S, Mitchell D, Halford H, Anderson M, Johnson C, Francis I, Bova J, Kenney P, Klippenstein D, Foster G, Turner D, Stillman A, Nelson R, Young S, Patt R, Rifkin M, Seltzer S, Gay S, Robison R, Sherwin P, Ballerini R. Safety and Efficacy of Mangafodipir Trisodium (MnDPDP) Injection for Hepatic MRI in Adults: Results of the U.S. Multicenter Phase III Clinical Trials (Safety). Journal Of Magnetic Resonance Imaging 2000, 12: 186-197. PMID: 10931579, DOI: 10.1002/1522-2586(200007)12:1<186::aid-jmri21>3.0.co;2-2.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal PainAdultAgedAged, 80 and overCardiovascular DiseasesContrast MediaDiagnosis, DifferentialEdetic AcidFemaleHumansImage EnhancementInjections, IntravenousLiver CirrhosisLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedPainPregnancyPyridoxal PhosphateRisk AssessmentSensitivity and SpecificityVomitingConceptsMagnetic resonance imagingMangafodipir trisodium injectionAdverse eventsMulticenter phase III clinical trialContrast-enhanced computed tomography examinationPhase III clinical trialsUnenhanced magnetic resonance imagingInjection of MnDPDPInjection-associated discomfortSerious adverse eventsShort-term safetyHepatic magnetic resonance imagingComputed tomography examinationSignificant short-term riskShort-term riskFocal liver lesionsClinical trialsTomography examinationLaboratory valuesLiver lesionsResonance imagingVital signsPatientsMnDPDPInjection
1994
Comparison of contrast enhanced CT and Mn-DPDP enhanced MRI for detection of focal hepatic lesions initial findings
Birnbaum B, Weinreb J, Fernandez M, Brown J, Rofsky N, Young S. Comparison of contrast enhanced CT and Mn-DPDP enhanced MRI for detection of focal hepatic lesions initial findings. Clinical Imaging 1994, 18: 21-27. PMID: 8180855, DOI: 10.1016/0899-7071(94)90141-4.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingMn-DPDPMore lesionsRetrospective multi-institutional studyExtensive metastatic diseaseHepatic magnetic resonance imagingMulti-institutional studyFocal hepatic diseaseFocal liver lesionsN'-dipyridoxylethylenediamineMetastatic diseaseIntravenous bolusDose groupFatty liverHepatic diseaseComparison of ContrastHepatic lesionsComputed tomographyLiver lesionsCT studiesPatientsMumol/Resonance imagingBolus contrastLesions